Sugi Predict

Sugi Predict / Compounds / SCHEMBL3126558

SCHEMBL3126558

SCHEMBL3126558

C=CCN1C(=O)/C(=C/c2ccc(-c3ccccc3)o2)SC1=S

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.80
▸ MEN1 O00255 2/20 0.80
▸ KMT2A Q03164 2/20 0.80
▸ MAPT P10636 3/20 0.66
▸ ALDH1A1 P00352 2/20 0.66
▸ LMNA P02545 1/20 0.66
▸ RAB9A P51151 1/20 0.66
▸ STAT3 P40763 1/20 0.60
▸ EP300 Q09472 1/20 0.59
▸ CREBBP Q92793 1/20 0.59
▸ APEX1 P27695 1/20 0.58
▸ HIF1AN Q9NWT6 1/20 0.58
▸ MAP3K5 Q99683 5/20 0.56
▸ EIF4E P06730 1/20 0.55
▸ EIF4G1 Q04637 1/20 0.55
▸ THRB P10828 1/20 0.55
▸ RECQL P46063 1/20 0.55
▸ MCL1 Q07820 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3126564 1.00 POLB (0.80) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL3126561 1.00 POLB (0.80) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL3892078 0.90 MEN1 (0.82) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL3892083 0.90 MEN1 (0.82) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL3900325 0.89 MEN1 (0.80) POLBMEN1KMT2ASTAT3EP300
SCHEMBL3895477 0.89 MEN1 (0.80) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL13762527 0.89 POLB (0.80) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL3895482 0.89 MEN1 (0.80) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL3900321 0.89 MEN1 (0.80) POLBMEN1KMT2ASTAT3EP300
SCHEMBL3134591 0.88 MEN1 (0.63) POLBMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 — — US claimed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 — — WO claimed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US claimed
US-20260124226-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-05-07 — — US disclosed
EP-4705284-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Emory University (US) 2026-03-11 — — EP disclosed
EP-4014975-B1 USE OF BROMOPHENOL-PYRAZOLINE COMPOUNDS IN THE TREATMENT OF PORCINE CORONAVIRUS DISEASES SHANDONG LINGHAI BIOTECHNOLOGY CO LTD (CN) 2026-01-28 — — EP disclosed
WO-2025235664-A1 PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2025-11-13 — — WO disclosed
US-20250282830-A1 ANTI-VIRAL PEPTIDE COMPOSITIONS AND METHODS TO IMPROVE BIOLOGICAL ACTIVITY THEREOF NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2025-09-11 — — US disclosed
CN-119548023-A Instant heating type coffee machine 莱捷科技(淮安)有限公司 2025-03-04 — — CN disclosed
CN-119246441-A Tea quality detection and analysis method and system 泉州市虹岩茶业有限公司 2025-01-03 — — CN disclosed
WO-2024233354-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2024-11-14 — — WO disclosed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 — — WO disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 — — WO disclosed
WO-2004043955-A1 RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RIGEL PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses MAVS, LAMP1, HAVCR2 POLB 4238/4885MEN1 4512/4885KMT2A 2561/4885
US-20260124226-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO NSUN2, SARS1, SNRPE POLB 1624/4885MEN1 4825/4885KMT2A 2511/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 POLB 433/4885MEN1 2869/4885KMT2A 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.